Imaging Caspase-3 Activation as a Marker of Apoptosis-Targeted Treatment Response in Cancer

Schmitt CA (2003) Senescence, apoptosis and therapy—cutting the lifelines of cancer. Nat Rev Cancer 3:286–295 Faber AC, Ebi H, Costa C, Engelman JA (2012) Apoptosis in targeted therapy responses: the role of BIM. Adv Pharmacol 65:519–542 Kaplan-Lefko PJ, Graves JD, Zoog SJ et al (2010) Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol Ther 9:618–631 Forero-Torres A, Shah J, Wood T et al (2010) Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biother Radiopharm 25:13–19 Vaillant F, Merino D, Lee L et al (2013) Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell 24:120–129 Brinkmann K, Hombach A, Seeger JM et al (2013) Second mitochondria-derived activator of caspase mimetic (SMAC) potentiates tumor susceptibility toward natural killer cell-mediated killing. Leuk Lymphoma 55(3):645–651 Allensworth JL, Sauer SJ, Lyerly HK et al (2013) Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-alpha-independent mechanism. Breast Cancer Res Treat 137:359–371 Ardecky RJ, Welsh K, Finlay D et al (2013) Design, synthesis and evaluation of inhibitor of apoptosis protein (IAP) antagonists that are highly selective for the BIR2 domain of XIAP. Bioorg Med Chem Lett 23:4253–4257 Cai Q, Sun H, Peng Y et al (2011) A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J Med Chem 54:2714–2726 Belhocine TZ, Blankenberg FG (2005) 99mTc-Annexin A5 uptake and imaging to monitor chemosensitivity. Methods Mol Med 111:363–380 Yagle KJ, Eary JF, Tait JF et al (2005) Evaluation of 18F-annexin V as a PET imaging agent in an animal model of apoptosis. J Nucl Med 46:658–666 Blankenberg FG, Kalinyak J, Liu L et al (2006) 99mTc-HYNIC-annexin V SPECT imaging of acute stroke and its response to neuroprotective therapy with anti-Fas ligand antibody. Eur J Nucl Med Mol Imaging 33:566–574 Madar I, Ravert H, Nelkin B et al (2007) Characterization of membrane potential-dependent uptake of the novel PET tracer 18F-fluorobenzyl triphenylphosphonium cation. Eur J Nucl Med Mol Imaging 34:2057–2065 Cohen A, Shirvan A, Levin G et al (2009) From the Gla domain to a novel small-molecule detector of apoptosis. Cell Res 19(5):625–637 Aloya R, Shirvan A, Grimberg H et al (2006) Molecular imaging of cell death in vivo by a novel small molecule probe. Apoptosis 11:2089–2101 Cohen A, Ziv I, Aloya T et al (2007) Monitoring of chemotherapy-induced cell death in melanoma tumors by N, N'-Didansyl-l-cystine. Technol Cancer Res Treat 6:221–234 Chen DL, Zhou D, Chu W et al (2012) Radiolabeled isatin binding to caspase-3 activation induced by anti-Fas antibody. Nucl Med Biol 39:137–144 Chen DL, Zhou D, Chu W et al (2009) Comparison of radiolabeled isatin analogs for imaging apoptosis with positron emission tomography. Nucl Med Biol 36:651–658 Chu W, Rothfuss J, Zhou D, Mach RH (2011) Synthesis and evaluation of isatin analogs as caspase-3 inhibitors: introduction of a hydrophilic group increases potency in a whole cell assay. Bioorg Med Chem Lett 21:2192–2197 Nguyen QD, Smith G, Glaser M et al (2009) Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide. Proc Natl Acad Sci U S A 106:16375–16380 Zhou D, Chu W, Rothfuss J et al (2006) Synthesis, radiolabeling, and in vivo evaluation of an 18F-labeled isatin analog for imaging caspase-3 activation in apoptosis. Bioorg Med Chem Lett 16:5041–5046 Faust A, Wagner S, Law MP et al (2007) The nonpeptidyl caspase binding radioligand (S)-1-(4-(2-[18F]Fluoroethoxy)-benzyl)-5-[1-(2-methoxymethylpyrrolidinyl)sulfonyl]isatin ([18F]CbR) as potential positron emission tomography-compatible apoptosis imaging agent. Q J Nucl Med Mol Imaging 51:67–73 Limpachayaporn P, Wagner S, Kopka K et al (2013) Synthesis, (18)F-radiolabeling, and in vivo biodistribution studies of N-fluorohydroxybutyl isatin sulfonamides using positron emission tomography. J Med Chem 56:4509–4520 Smith G, Glaser M, Perumal M et al (2008) Design, synthesis, and biological characterization of a caspase 3/7 selective isatin labeled with 2-[18F]fluoroethylazide. J Med Chem 51:8057–8067 Zhou D, Lee H, Rothfuss JM et al (2009) Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fluoropropyl)-4-methyl-pyridin-2-amine as a potential PET tracer for inducible nitric oxide synthase. J Med Chem 52:2443–2453 Nguyen QD, Lavdas I, Gubbins J et al (2013) Temporal and spatial evolution of therapy-induced tumor apoptosis detected by caspase-3-selective molecular imaging. Clin Cancer Res 19(14):3914–3924 Zhou D, Chu W, Chen DL et al (2009) [18F]- and [11C]-labeled N-benzyl-isatin sulfonamide analogues as PET tracers for apoptosis: synthesis, radiolabeling mechanism, and in vivo imaging study of apoptosis in Fas-treated mice using [11C]WC-98. Org Biomol Chem 7:1337–1348 Chu W, Zhang J, Zeng C et al (2005) N-benzylisatin sulfonamide analogues as potent caspase-3 inhibitors: synthesis, in vitro activity, and molecular modeling studies. J Med Chem 48:7637–7647 Al-Ejeh F, Darby JM, Tsopelas C et al (2009) APOMAB, a La-specific monoclonal antibody, detects the apoptotic tumor response to life-prolonging and DNA-damaging chemotherapy. PLoS ONE 4:e4558 Li J, Knee DA, Wang Y et al (2008) LBY135, a novel anti-DR5 agonistic antibody induces tumor cell-specific cytotoxic activity in human colon tumor cell lines and xenografts. Drug Dev Res 69:69–82 Kumar S (2004) Measurement of caspase activity in cells undergoing apoptosis. In: Brady HJM (ed) Apoptosis methods and protocols. Humana Press, Inc., Totowa, pp 19–30 Chu W, Rothfuss J, d'Avignon A et al (2007) Isatin sulfonamide analogs containing a Michael addition acceptor: a new class of caspase 3/7 inhibitors. J Med Chem 50:3751–3755 Witney TH, Fortt RR, Aboagye EO (2014) Preclinical assessment of carboplatin treatment efficacy in lung cancer by 18F-ICMT-11-positron emission tomography. PLoS ONE 9:e91694 Challapalli A, Kenny LM, Hallett WA et al (2013) 18F-ICMT-11, a caspase-3-specific PET tracer for apoptosis: biodistribution and radiation dosimetry. J Nucl Med 54:1551–1556